Registry for managing aneurysmal subarachnoid hemorrhage in Switzerland

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects clinical and management data from patients treated for aneurysmal subarachnoid hemorrhage (aSAH) across various hospitals in Switzerland. It aims to assess the current standard of care and patient outcomes, including neuropsychological assessments. By pooling data into a common database, the registry serves as a critical tool for healthcare providers to evaluate care quality and foster scientific collaboration on aSAH management. The initiative seeks to recruit all aSAH patients in Switzerland to provide a comprehensive assessment of incidence and treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion criteria:

\- Patients admitted with a proven diagnosis of aneurysmal subarachnoid hemorrhage.

Exclusion criteria:

\- Patients in whom the source of haemorrhage could not be identified (angiogram-negative SAH) or SAH with other causes than cerebral aneurysms.

Where it's running

• Kantonsspital Aarau
  Aarau, Canton of Aargau, Switzerland Recruiting
• Geneva University Hospital
  Geneva, Canton of Geneva, Switzerland Recruiting
• Kantonsspital St. Gallen
  Sankt Gallen, Canton of St. Gallen, Switzerland Recruiting
• University Hospital Basel
  Basel, Switzerland Recruiting
• University Hospital Bern
  Bern, Switzerland Recruiting
• University Hospital Lausanne
  Lausanne, Switzerland Recruiting

Study contacts

• Principal investigator: Bawarjan Schatlo, MD — University Hospital, Geneva
• Study coordinator: Karl Schaller, MD
• Email: karl.schaller@hcuge.ch
• Phone: +41223728202

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Smartphone-based EEG to detect hidden awareness in ICU patients with brain injuries

  Researchers will test a smartphone-enabled EEG to see if it can reveal Cognitive Motor Dissociation in ICU patients who can’t show commands at bedside.

  Recruiting Columbia University · Miami, Florida and 8 other locations · NCT07917728

• French validation of the SAHOT outcome tool after subarachnoid hemorrhage

  This study tests whether a French version of the SAHOT questionnaire reliably measures outcomes in adults after subarachnoid hemorrhage.

  Recruiting Fondation Ophtalmologique Adolphe de Rothschild · Paris · NCT07894666

• Flow Diverter Stent for Intracranial Aneurysm in China

  This study tests a novel flow diverter stent to treat intracranial aneurysms in adults and follows patients through treatment and follow-up.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07821957

• Real-World Experience With the WEB Device for Intracranial Aneurysms

  This study tests how well the Woven EndoBridge device works in routine treatment of intracranial aneurysms in China across multiple centers.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07620626

• Choydar flow-directed mesh stent for unruptured brain aneurysms

  This trial tests the Choydar flow-directed mesh stent to see if it is safe and works for people with unruptured intracranial aneurysms in the internal carotid or vertebral arteries.

  Recruiting at 8 sites Johnson & Johnson Medical (Shanghai) Ltd. · Chenzhou and 7 other locations · NCT07228312

• Pivotal test of the Silk Vista Baby Flow Diverter for unruptured brain aneurysms

  This study tests whether the Silk Vista Baby flow diverter can safely and effectively treat a single unruptured intracranial aneurysm in adults 22–80 years old.

  Recruiting at 6 sites Balt USA · Thousand Oaks, California and 5 other locations · NCT07225075

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.